Table 2.
Summary of demographic and clinical data by HLA-DRB1*1501 haplotype
| HLA-DRB1*1501 | Mean | SD | Median | P-value | |
|---|---|---|---|---|---|
| Age (Y) | 1501+ | 41.4 | 9.9 | 41 | 0.116 |
| 1501− | 42.7 | 9.8 | 43 | ||
| Gender | 1501+ F: 171(74%); M: 60 (26%) | 0.009 | |||
| 1501− F: 173(63%); M: 101(37%) | |||||
| Age of disease onset (Y) | 1501+ | 32.4 | 8.8 | 32 | 0.025 |
| 1501− | 34.3 | 9.7 | 34 | ||
| Disease duration (Y) | 1501+ | 9.99 | 8.5 | 7.0 | 0.170 |
| 1501− | 9.41 | 9.2 | 6.0 | ||
| MS treatment exposure | 1501+ YES: 163(71%); NO: 68(29%) | 0.462 | |||
| 1501− YES: 185(68%); NO: 89(32%) | |||||
| HLA-DRB1*1501 | 1501+ 232 (46%) | 0.609 | |||
| 1501− 273 (54%) | |||||
| EDSS score | 1501+ | 1.9 | 1.6 | 1.5 | 0.201 |
| 1501− | 2.1 | 1.7 | 2.0 | ||
| MSFC score | 1501+ | 0.082 | 0.631 | 0.197 | 0.434 |
| 1501− | 0.034 | 0.710 | 0.223 | ||
| 9-Hole peg testa | 1501+ | 0.003 | 0.958 | 0.116 | 0.738 |
| 1501− | 0.017 | 1.027 | 0.097 | ||
| PASAT-3a | 1501+ | 0.110 | 1.070 | −0.128 | 0.004 |
| 1501− | 0.048 | 0.935 | 0.266 | ||
| 25-FTWa | 1501+ | 0.017 | 0.789 | −0.0001 | 0.119 |
| 1501− | 0.120 | 1.149 | 0.0329 | ||
| T2-Lesion load (mm3) | 1501+ | 8109.8 | 13006 | 3337.1 | 0.031 |
| 1501− | 6786.2 | 10137 | 2828.5 | ||
| Normalized brain | 1501+ | 1585.9 | 90.3 | 1589.6 | 0.023 |
| parenchymal volume (cm3) | 1501− | 1591.4 | 88.6 | 1607.6 | |
| Volume scaling factor | 1501+ | 1.33 | 0.11 | 1.33 | 0.600 |
| 1501− | 1.34 | 0.12 | 1.33 |
a Z Score. Y = years; F = female; M = male; EDSS = expanded disability status scale; MSFC = multiple sclerosis functional composite; PASAT = paced auditory serial addition test; 25-FTW = 25-Foot timed walk.